StockData
Kura Oncology, Inc. logo

Kura Oncology, Inc. (KURA) company profile

KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)

Close on Nov 18, 2026Market cap $652.97MP/E –Yield –

About Kura Oncology

Pharmaceutical Preparations, SIC 2834

Kura Oncology, Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes precision medicines for the treatment of cancer. The company focuses on small-molecule drug candidates that target cancer signaling pathways to address unmet needs in oncology and hematology. Its approved product is KOMZIFTI (ziftomenib), an oral menin inhibitor administered once daily. The company also advances drug candidates across clinical trials, including evaluation in combination therapies for acute myeloid leukemia. Its therapies primarily serve adult cancer patients, particularly those diagnosed with relapsed or refractory acute myeloid leukemia harboring susceptible nucleophosmin 1 mutations.

The company conducts its business and clinical operations within the United States and collaborates with global partners, including Kyowa Kirin. Its activities include regulatory development, research, and commercial distribution of its oncology therapies. Kura Oncology is headquartered in San Diego, California.

Summary of the business section of Kura Oncology's latest annual report, written by StockData.

Company profile

Company

Legal name
Kura Oncology, Inc.
Founded
2014
Headquarters
San Diego, CA
Address
4930 Directors Place, Suite 500 92121
Phone
(858) 500-8800
Employees
260, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, CA USA

Stock & identifiers

Ticker
KURA
Exchange
Nasdaq
IPO date
Sep 16, 2015
Shares outstanding
89M, Aug 7, 2026
Public float
$496.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1422143
CUSIP
50127T109
ISIN
US50127T1097
FIGI
BBG008974342
Share class FIGI
BBG008974351
LEI
5493005QORQTZCZYOP39
EIN
61-1547851

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Troy Edward WilsonPresident and CEO, Director1,414,650
Thomas James DoyleSVP, Finance & Accounting138,581
Kathleen FordChief Operating Officer132,276
Brian T. PowlChief Commercial Officer113,265
Teresa Brophy BairChief Legal Officer178,401
Mollie LeoniChief Medical Officer99,845
Francis BurrowsChief Scientific Officer63,053
Jennifer FulkChief Financial Officer–
Helen Louise CollinsDirector–
Diane L. ParksDirector–
Faheem HasnainDirector23,983
Mary T. SzelaDirector–
Thomas MalleyDirector149,557
Michael VasconcellesDirector–
Carol SchaferDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.74M$6.49M$2.29M$84–
FY2024$6.24M$4.23M$2.43M$70–
FY2023$5.25M$5.95M$2.20M$116–
FY2022$5.30M$3.95M$2.54M$90$114
FY2021$8.74M-$3.56M$3.56M$102$126
FY2020$4.19M$13.89M$2.26M$238$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Troy E. Wilson, Ph.D., J.D.
President and Chief Executive Officer
$700.00K–$3.30M$630.00K$107.77K$4.74M-24%
Brian Powl
Chief Commercial Officer
$506.35K$1.37M$487.99K$291.15K$17.50K$2.67M–
Kathleen Ford
Chief Operating Officer
$539.94K–$975.99K$310.46K$76.10K$1.90M-24%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 260 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 4, 2015ListingRegistration of securities on an exchange (Form 8-A)
Mar 12, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 12, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 10, 2015Name changeName changed from ZETA ACQUISITION CORP III to Kura Oncology, Inc.

See a number that looks wrong?